Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

M A Calderon, P Demoly, T Casale, C A Akdis, C Bachert, M Bewick, B M Bilò, B Bohle, S Bonini, A Bush, D P Caimmi, G W Canonica, V Cardona, A M Chiriac, L Cox, A Custovic, F De Blay, P Devillier, A Didier, G Di Lorenzo, G Du Toit, S R Durham, P Eng, A Fiocchi, A T Fox, R Gerth van Wijk, R M Gomez, T Haathela, S Halken, P W Hellings, L Jacobsen, J Just, L K Tanno, J Kleine-Tebbe, L Klimek, E F Knol, P Kuna, D E Larenas-Linnemann, A Linneberg, M Matricardi, H J Malling, R Moesges, J Mullol, A Muraro, N Papadopoulos, G Passalacqua, E Pastorello, O Pfaar, D Price, P Rodriguez Del Rio, R Ruëff, B Samolinski, G K Scadding, G Senti, M H Shamji, A Sheikh, J C Sisul, D Sole, G J Sturm, A Tabar, R Van Ree, M T Ventura, C Vidal, E M Varga, M Worm, T Zuberbier, J Bousquet, M A Calderon, P Demoly, T Casale, C A Akdis, C Bachert, M Bewick, B M Bilò, B Bohle, S Bonini, A Bush, D P Caimmi, G W Canonica, V Cardona, A M Chiriac, L Cox, A Custovic, F De Blay, P Devillier, A Didier, G Di Lorenzo, G Du Toit, S R Durham, P Eng, A Fiocchi, A T Fox, R Gerth van Wijk, R M Gomez, T Haathela, S Halken, P W Hellings, L Jacobsen, J Just, L K Tanno, J Kleine-Tebbe, L Klimek, E F Knol, P Kuna, D E Larenas-Linnemann, A Linneberg, M Matricardi, H J Malling, R Moesges, J Mullol, A Muraro, N Papadopoulos, G Passalacqua, E Pastorello, O Pfaar, D Price, P Rodriguez Del Rio, R Ruëff, B Samolinski, G K Scadding, G Senti, M H Shamji, A Sheikh, J C Sisul, D Sole, G J Sturm, A Tabar, R Van Ree, M T Ventura, C Vidal, E M Varga, M Worm, T Zuberbier, J Bousquet

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Keywords: AIRWAYS ICPs; Ageing; Allergen immunotherapy; Asthma; EIP on AHA; Rhinitis.

References

    1. Rechel B, Grundy E, Robine JM, Cylus J, Mackenbach JP, Knai C, et al. Ageing in the European Union. Lancet. 2013;381(9874):1312–1322. doi: 10.1016/S0140-6736(12)62087-X.
    1. Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The European Innovation Partnership on Active and Healthy Ageing: the European geriatric medicine introduces the EIP on AHA column. Eur Geriatr Med. 2014;5(6):361–362. doi: 10.1016/j.eurger.2014.09.010.
    1. Bousquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes NH, et al. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. Eur Respir J. 2016;47(4):1028–1033. doi: 10.1183/13993003.01856-2015.
    1. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs) Eur Respir J. 2014;44(2):304–323. doi: 10.1183/09031936.00014614.
    1. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Allergy. 2007;62(3):216–223. doi: 10.1111/j.1398-9995.2007.01307.x.
    1. Bourret R, Bousquet J, Mercier J, Camuzat T, Bedrook A, Demoly P, et al. MASK rhinitis, a single tool for integrated care pathways in allergic rhinitis. World Hosp Health Serv. 2015;51(3):36–39.
    1. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372–1392. doi: 10.1111/all.12686.
    1. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367.e2–374.e2. doi: 10.1016/j.jaci.2016.03.025.
    1. Hellings PW, Muraro A, Fokkens W, Mullol J, Bachert C, Canonica GW, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clin Transl Allergy. 2015;5:36. doi: 10.1186/s13601-015-0080-9.
    1. Price D, Smith P, Hellings P, Papadopoulos N, Fokkens W, Muraro A, et al. Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol. 2015;11(11):1205–1217. doi: 10.1586/1744666X.2015.1081814.
    1. Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) Clin Transl Allergy. 2016;6:29. doi: 10.1186/s13601-016-0116-9.
    1. Bousquet J, Anto JM, Berkouk K, Gergen P, Antunes JP, Auge P, et al. Developmental determinants in non-communicable chronic diseases and ageing. Thorax. 2015;70(6):595–597. doi: 10.1136/thoraxjnl-2014-206304.
    1. Samolinski B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ, et al. Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy. 2012;67(6):726–731. doi: 10.1111/j.1398-9995.2012.02822.x.
    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–836. doi: 10.1016/j.jaci.2003.12.591.
    1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) Allergy. 2008;63(Suppl. 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.
    1. Bousquet J, Khaltaev N. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. In: Global alliance against chronic respiratory diseases. Geneva: World Health Organization; 2007. ISBN: 978-92-4-156346-8.
    1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494. doi: 10.1056/NEJMra074081.
    1. Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax. 1999;54(3):268–272. doi: 10.1136/thx.54.3.268.
    1. Weinmayr G, Forastiere F, Weiland SK, Rzehak P, Abramidze T, Annesi-Maesano I, et al. International variation in prevalence of rhinitis and its relationship with sensitisation to perennial and seasonal allergens. Eur Respir J. 2008;32(5):1250–1261. doi: 10.1183/09031936.00157807.
    1. Bousquet PJ, Leynaert B, Neukirch F, Sunyer J, Janson CM, Anto J, et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy. 2008;63(10):1301–1309. doi: 10.1111/j.1398-9995.2008.01824.x.
    1. Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy. 2008;63(7):842–853. doi: 10.1111/j.1398-9995.2008.01715.x.
    1. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004;34(4):520–526. doi: 10.1111/j.1365-2222.2004.1935.x.
    1. Anandan C, Gupta R, Simpson CR, Fischbacher C, Sheikh A. Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med. 2009;102(10):431–442. doi: 10.1258/jrsm.2009.090027.
    1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl.):S147–S334. doi: 10.1067/mai.2001.118891.
    1. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. J Allergy Clin Immunol. 2007;120(2):381–387. doi: 10.1016/j.jaci.2007.03.034.
    1. Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al. Unmet needs in severe chronic upper airway disease (SCUAD) J Allergy Clin Immunol. 2009;124(3):428–433. doi: 10.1016/j.jaci.2009.06.027.
    1. Haahtela T, Valovirta E, Kauppi P, Tommila E, Saarinen K, von Hertzen L, et al. The Finnish allergy programme 2008—2018—scientific rationale and practical implementation. Asia Pac Allergy. 2012;2(4):275–279. doi: 10.5415/apallergy.2012.2.4.275.
    1. Bousquet J, Anto JM, Akdis M, Auffray C, Keil T, Momas I, et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story. Allergy. 2016;71(11):1513–1525. doi: 10.1111/all.12880.
    1. Bousquet J, Anto JM, Wickman M, Keil T, Valenta R, Haahtela T, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy. 2015;70(9):1062–1078. doi: 10.1111/all.12637.
    1. Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012;130(4):894.e5–901.e5. doi: 10.1016/j.jaci.2012.05.053.
    1. Asarnoj A, Hamsten C, Waden K, Lupinek C, Andersson N, Kull I, et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: a BAMSE/MeDALL study. J Allergy Clin Immunol. 2016;137(3):813–821. doi: 10.1016/j.jaci.2015.09.052.
    1. Westman M, Lupinek C, Bousquet J, Andersson N, Pahr S, Baar A, et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol. 2015;135(5):1199 e1–11–1206 e1–11. doi: 10.1016/j.jaci.2014.10.042.
    1. Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med. 2014;2(2):131–140. doi: 10.1016/S2213-2600(13)70277-7.
    1. Simpson A, Lazic N, Belgrave DC, Johnson P, Bishop C, Mills C, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. J Allergy Clin Immunol. 2015;136(5):1224–1231. doi: 10.1016/j.jaci.2015.03.027.
    1. Ballardini N, Bergstrom A, Wahlgren CF, van Hage M, Hallner E, Kull I, et al. IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence. Allergy. 2016;71(3):342–349. doi: 10.1111/all.12798.
    1. Belgrave DC, Granell R, Simpson A, Guiver J, Bishop C, Buchan I, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748.
    1. Melioli G, Bonifazi F, Bonini S, Maggi E, Mussap M, Passalacqua G, et al. The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clin Biochem. 2011;44(12):1005–1011. doi: 10.1016/j.clinbiochem.2011.05.007.
    1. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385(9971):899–909. doi: 10.1016/S0140-6736(14)60446-3.
    1. Kotz D, Simpson CR, Viechtbauer W, van Schayck OC, Sheikh A. Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. NPJ Prim Care Respir Med. 2014;24:14011.
    1. Smith AM, Villareal M, Bernstein DI, Swikert DJ. Asthma in the elderly: risk factors and impact on physical function. Ann Allergy Asthma Immunol. 2012;108(5):305–310. doi: 10.1016/j.anai.2012.02.022.
    1. Bellia V, Pedone C, Catalano F, Zito A, Davi E, Palange S, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132(4):1175–1182. doi: 10.1378/chest.06-2824.
    1. Moscato G, Pala G, Boillat MA, Folletti I, Gerth van Wijk R, Olgiati-Des Gouttes D, et al. EAACI position paper: prevention of work-related respiratory allergies among pre-apprentices or apprentices and young workers. Allergy. 2011;66(9):1164–1173. doi: 10.1111/j.1398-9995.2011.02615.x.
    1. Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, et al. Early life origins of chronic obstructive pulmonary disease. Thorax. 2010;65(1):14–20. doi: 10.1136/thx.2008.112136.
    1. Jarvis D, Burney P. ABC of allergies. The epidemiology of allergic disease. BMJ. 1998;316(7131):607–610. doi: 10.1136/bmj.316.7131.607.
    1. Linneberg A. Changes in atopy over 25 years: allergy epidemic has spread to old age. BMJ. 2005;331(7512):352. doi: 10.1136/bmj.331.7512.352.
    1. Law M, Morris JK, Wald N, Luczynska C, Burney P. Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ. 2005;330(7501):1187–1188. doi: 10.1136/.
    1. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN. Allergy. 2007;62(Suppl 84):1–41. doi: 10.1111/j.1398-9995.2007.01551.x.
    1. Song WJ, Sohn KH, Kang MG, Park HK, Kim MY, Kim SH, et al. Urban-rural differences in the prevalence of allergen sensitization and self-reported rhinitis in the elderly population. Ann Allergy Asthma Immunol. 2015;114(6):455–461. doi: 10.1016/j.anai.2015.03.008.
    1. Wuthrich B, Schmid-Grendelmeier P, Schindler C, Imboden M, Bircher A, Zemp E, et al. Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population. Int Arch Allergy Immunol. 2013;162(2):143–148. doi: 10.1159/000351416.
    1. Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012;23(4):300–306. doi: 10.1111/j.1399-3038.2012.01313.x.
    1. Calderon MA, Casale T, Cox L, Akdis CA, Burks AW, Nelson HS, et al. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2013;68(7):825–828. doi: 10.1111/all.12180.
    1. Dhami S, Nurmatov U, Agache I, Lau S, Muraro A, Jutel M, et al. Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl Allergy. 2015;6:5. doi: 10.1186/s13601-016-0094-y.
    1. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358–368. doi: 10.1016/j.jaci.2015.12.1300.
    1. Haahtela T, von Hertzen L, Makela M, Hannuksela M. Finnish allergy programme 2008–2018—time to act and change the course. Allergy. 2008;63(6):634–645. doi: 10.1111/j.1398-9995.2008.01712.x.
    1. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338–1345. doi: 10.1016/j.jaci.2007.07.046.
    1. Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725. doi: 10.1001/jama.2016.3964.
    1. Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. doi: 10.1186/s13601-015-0083-6.
    1. Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68(1):1–7. doi: 10.1111/all.12040.
    1. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717.e5–725.e5. doi: 10.1016/j.jaci.2011.12.973.
    1. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128(3):559–566. doi: 10.1016/j.jaci.2011.06.022.
    1. Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy. 2005;60(1):1–3. doi: 10.1111/j.1398-9995.2005.00700.x.
    1. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy. 2011;41(9):1235–1246. doi: 10.1111/j.1365-2222.2011.03804.x.
    1. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014;124(11):4678–4680. doi: 10.1172/JCI78891.
    1. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82(3 Pt 1):439–446. doi: 10.1016/0091-6749(88)90017-6.
    1. James LK, Bowen H, Calvert RA, Dodev TS, Shamji MH, Beavil AJ, et al. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol. 2012;130(3):663–670. doi: 10.1016/j.jaci.2012.04.006.
    1. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17. doi: 10.1186/s40413-015-0063-2.
    1. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT) Allergy. 2011;66(6):740–752. doi: 10.1111/j.1398-9995.2011.02583.x.
    1. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011;41(9):1263–1272. doi: 10.1111/j.1365-2222.2011.03835.x.
    1. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288 e3–1296 e3. doi: 10.1016/j.jaci.2013.01.049.
    1. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278–1288. doi: 10.1001/jama.2013.2049.
    1. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD) Allergo J Int. 2014;23(8):282–319. doi: 10.1007/s40629-014-0032-2.
    1. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(8):1301–1309. doi: 10.1001/jamainternmed.2015.2840.
    1. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi: 10.1186/1939-4551-7-6.
    1. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–568. doi: 10.1016/j.jaci.2015.04.047.
    1. Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol. 2007;142(1):70–78. doi: 10.1159/000096001.
    1. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. doi: 10.1111/j.1398-9995.2007.01451.x.
    1. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) J Allergy Clin Immunol. 2002;109(2):251–256. doi: 10.1067/mai.2002.121317.
    1. Valovirta E, Berstad AK, de Blic J, Bufe A, Eng P, Halken S, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33(10):1537–1546. doi: 10.1016/j.clinthera.2011.09.013.
    1. Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14(4):363–370. doi: 10.1097/ACI.0000000000000084.
    1. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):vi, xi–xiv, 1–322.
    1. Holt PG, Strickland D, Bosco A, Belgrave D, Hales B, Simpson A, et al. Distinguishing benign from pathologic TH2 immunity in atopic children. J Allergy Clin Immunol. 2016;137(2):379–387. doi: 10.1016/j.jaci.2015.08.044.
    1. Holt PG, Sly PD, Sampson HA, Robinson P, Loh R, Lowenstein H, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013;132(4):991 e1–993 e1. doi: 10.1016/j.jaci.2013.04.049.
    1. Zolkipli Z, Roberts G, Cornelius V, Clayton B, Pearson S, Michaelis L, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol. 2015;136(6):1541–1547. doi: 10.1016/j.jaci.2015.04.045.
    1. Glovsky MM, Ghekiere L, Rejzek E. Effect of maternal immunotherapy on immediate skin test reactivity, specific rye I IgG and IgE antibody, and total IgE of the children. Ann Allergy. 1991;67(1):21–24.
    1. Matricardi PM. Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? Pediatr Allergy Immunol. 2014;25(1):15–18. doi: 10.1111/pai.12200.
    1. Ranciere F, Nikasinovic L, Bousquet J, Momas I. Onset and persistence of respiratory/allergic symptoms in preschoolers: new insights from the PARIS birth cohort. Allergy. 2013;68(9):1158–1167.
    1. Garcia-Aymerich J, Benet M, Saeys Y, Pinart M, Basagana X, Smit HA, et al. Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity cluster. Allergy. 2015;70(8):973–984. doi: 10.1111/all.12640.
    1. Amat F, Saint-Pierre P, Bourrat E, Nemni A, Couderc R, Boutmy-Deslandes E, et al. Early-onset atopic dermatitis in children: which are the phenotypes at risk of asthma? Results from the ORCA cohort. PLoS One. 2015;10(6):e0131369. doi: 10.1371/journal.pone.0131369.
    1. Just J, Deslandes-Boutmy E, Amat F, Desseaux K, Nemni A, Bourrat E, et al. Natural history of allergic sensitization in infants with early-onset atopic dermatitis: results from ORCA study. Pediatr Allergy Immunol. 2014;25(7):668–673. doi: 10.1111/pai.12287.
    1. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69(7):854–867. doi: 10.1111/all.12383.
    1. Burnay E, Cruz-Correia R, Jacinto T, Sousa AS, Fonseca J. Challenges of a mobile application for asthma and allergic rhinitis patient enablement-interface and synchronization. Telemed J e-Health. 2013;19(1):13–18. doi: 10.1089/tmj.2012.0020.
    1. Morais-Almeida M, Pite H, Pereira AM, Todo-Bom A, Nunes C, Bousquet J, et al. Prevalence and classification of rhinitis in the elderly: a nationwide survey in Portugal. Allergy. 2013;68(9):1150–1157.
    1. Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, et al. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016;27(2):126–133. doi: 10.1111/pai.12540.
    1. Wahn U. Assessing rhinitis symptoms in children—a need for action. Pediatr Allergy Immunol. 2016;27(2):114–116. doi: 10.1111/pai.12541.
    1. Soyiri IN, Nwaru BI, Sheikh A. Patient-reported outcome measures for allergy and asthma in children. Pediatr Allergy Immunol. 2016
    1. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40–47. doi: 10.2500/aap.2015.36.3823.
    1. Worth A, Hammersley V, Knibb R, Flokstra-de-Blok B, DunnGalvin A, Walker S, et al. Patient-reported outcome measures for asthma: a systematic review. NPJ Prim Care Respir Med. 2014;24:14020.
    1. Canonica GW, Bachert C, Hellings P, Ryan D, Valovirta E, Wickman M, et al. Allergen immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J. 2015;8(1):31. doi: 10.1186/s40413-015-0079-7.
    1. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322–1333. doi: 10.1183/13993003.00780-2015.
    1. Loza MJ, Adcock I, Auffray C, Chung KF, Djukanovic R, Sterk PJ, et al. Longitudinally stable, clinically defined clusters of patients with asthma independently identified in the ADEPT and U-BIOPRED asthma studies. Ann Am Thorac Soc. 2016;13(Suppl. 1):S102–S103.
    1. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi: 10.1183/13993003.00779-2015.
    1. Nolte M, Barber D, Maloney J, Li Z, Kaur A, Galan A, et al. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2015;115(6):509.e2–515.e2. doi: 10.1016/j.anai.2015.09.018.
    1. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393–1405. doi: 10.1111/all.12698.
    1. Gueguen C, Bouley J, Moussu H, Luce S, Duchateau M, Chamot-Rooke J, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016;137(2):545–558. doi: 10.1016/j.jaci.2015.09.015.
    1. Bousquet J, Jorgensen C, Dauzat M, Cesario A, Camuzat T, Bourret R, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des. 2014;20(38):5928–5944. doi: 10.2174/1381612820666140314115505.
    1. Tripodi S, Frediani T, Lucarelli S, Macri F, Pingitore G, Di Rienzo BusincoA, et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol. 2012;129(3):834.e8–839.e8. doi: 10.1016/j.jaci.2011.10.045.
    1. Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MC. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645.e1–8–1652.e1–8. doi: 10.1016/j.jaci.2015.03.041.
    1. Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo BusincoA, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol. 2014;134(1):75–81. doi: 10.1016/j.jaci.2014.01.042.
    1. Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy. 1986;56(6):456–459.
    1. Kuitunen M, Englund H, Remes S, Moverare R, Pelkonen A, Borres MP, et al. High IgE levels to alpha-lactalbumin, beta-lactoglobulin and casein predict less successful cow’s milk oral immunotherapy. Allergy. 2015;70(8):955–962. doi: 10.1111/all.12647.
    1. Oykhman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy. Allergy Asthma Clin Immunol. 2015;11:31. doi: 10.1186/s13223-015-0096-7.
    1. Tam H, Calderon MA, Manikam L, Nankervis H, Garcia Nunez I, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev. 2016;2:CD008774.
    1. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59(1):45–53. doi: 10.1046/j.1398-9995.2003.00387.x.
    1. Larenas Linnemann DE, Blaiss MS. Selection of patients for sublingual versus subcutaneous immunotherapy. Immunotherapy. 2014;6(7):871–884. doi: 10.2217/imt.14.55.
    1. Bousquet J, Schunemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2 LEN statement. Allergy. 2011;66(6):765–774. doi: 10.1111/j.1398-9995.2011.02590.x.
    1. Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy. 2009;64(12):1737–1745. doi: 10.1111/j.1398-9995.2009.02232.x.
    1. Bachert C, Larche M, Bonini S, Canonica GW, Kundig T, Larenas-Linnemann D, et al. Allergen immunotherapy on the way to product-based evaluation—a WAO statement. World Allergy Organ J. 2015;8(1):29. doi: 10.1186/s40413-015-0078-8.
    1. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol. 2012;12(3):249–256. doi: 10.1097/ACI.0b013e32835358b3.
    1. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131(4):1084–1091. doi: 10.1016/j.jaci.2012.12.662.
    1. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608–613. doi: 10.1016/j.jaci.2005.06.004.
    1. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951–960. doi: 10.1016/j.jaci.2008.09.017.
    1. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. doi: 10.1111/j.1365-2222.2008.03121.x.
    1. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–140. doi: 10.1016/j.jaci.2005.09.036.
    1. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389. doi: 10.1016/j.jaci.2009.11.022.
    1. Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M, et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. J Allergy Clin Immunol. 2016;137(2):452.e9–461.e9. doi: 10.1016/j.jaci.2015.08.046.
    1. Matui P, Wyatt JC, Pinnock H, Sheikh A, McLean S. Computer decision support systems for asthma: a systematic review. NPJ Prim Care Respir Med. 2014;24:14005.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться